Chinese Biopharma Firm Apollomics Completes $120M Financing
Apollomics, Inc., an innovative biopharmaceutical company dedicated to the discovery and development of new tumor-targeting and immune drugs and their combination therapies, announced that it has completed more than US$120 million in Series C financing. The financing was led by Ping An Capital, followed by several new and existing investors, and Huaxing Capital served as…
